{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:44:35Z","timestamp":1791981875565,"version":"4.4.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Circulating tumor DNA (ctDNA) has emerged as a noninvasive technique that provides valuable insights into molecular profiles and tumor disease management. This study aimed to evaluate the prognostic significance of circulating tumor DNA (ctDNA) in urothelial carcinoma (UC) through a systematic review and meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A comprehensive search was conducted in MEDLINE, EMBASE, and the Cochrane Library from the inception to December 2023. Studies investigating the prognostic value of ctDNA in UC were included. Hazard ratios (HRs) of disease-free survival (DFS) and overall survival (OS) were extracted. Overall meta-analysis and subgroup exploration stratified by metastatic status, ctDNA sampling time, treatment type, and detection method was performed using the R software (version 4.2.2).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 16 studies with 1725 patients were included. Fourteen studies assessed the association between baseline ctDNA status and patient outcomes. Patients with elevated ctDNA levels exhibited significantly worse DFS (HR=6.26; 95% CI: 3.71\u201310.58, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) and OS (HR=4.23; 95% CI: 2.72\u20136.57, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) regardless of metastatic status, ctDNA sampling time, treatment type, and detection methods. Six studies evaluated the prognostic value of ctDNA dynamics in UC. Patients who showed a decrease or clearance in ctDNA levels during treatment or observation demonstrated more favorable DFS (HR=0.26, 95% CI: 0.17\u20130.41, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) and OS (HR=0.21, 95% CI: 0.11\u20130.38, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) compared to those who did not. The association remained consistent across the subgroup analysis based on metastatic status and detection methods. In the immune checkpoint inhibitor-treated setting, both lower baseline ctDNA level and ctDNA decrease during the treatment were significantly associated with more favorable oncologic outcomes. Furthermore, specific gene mutations such as FGFR3 identified in ctDNA also demonstrated predictive value in UC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis demonstrates a strong association of ctDNA status and its dynamic change with survival outcomes in UC, suggesting substantial clinical utility of ctDNA testing in prognosis prediction and decision making in this setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000001372","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T10:01:18Z","timestamp":1712224878000},"page":"3923-3936","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"110","author":[{"given":"Haoyang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengnian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Device Regulatory Research and Evaluation Center, West China Hospital, Sichuan University, Chengdu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banghua","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6]]},"reference":[{"key":"R1-20250824","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part b: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20250824","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma\u00a0- upper tract, lower tract and metastatic disease","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"R7-20250824","first-page":"176","article-title":"Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"R9-20250824","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin Chim Acta"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"e2026921","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"103187","DOI":"10.1016\/j.critrevonc.2020.103187","article-title":"Circulating tumour DNA and melanoma survival: a systematic literature review and meta-analysis","volume":"157","author":"Gandini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"103771","DOI":"10.1016\/j.critrevonc.2022.103771","article-title":"Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: evidence from a meta-analysis","volume":"177","author":"Wang","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"102362","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.3390\/ijms241210230","article-title":"Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Chidharla","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"e005854","DOI":"10.1136\/jitc-2022-005854","article-title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review","volume":"11","author":"Al-Showbaki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.7150\/ijbs.44024","article-title":"Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma","volume":"16","author":"Wu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"e001406","DOI":"10.1136\/jitc-2020-001406","article-title":"Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report","volume":"9","author":"Blumendeller","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br J Cancer"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euo.2019.08.004","article-title":"Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer","volume":"4","author":"Chalfin","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating Tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.3390\/ijms231911732","article-title":"Cell-Free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"v508","DOI":"10.1093\/annonc\/mdz253.069","article-title":"1243P - Tumour mutation burden (TMB), PD-L1, IFN-\u03b3 signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)","volume":"30","author":"Massard","year":"2019","journal-title":"Ann Oncol"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"16578","DOI":"10.3390\/ijms242316578","article-title":"Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer","volume":"24","author":"Carrasco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel use of circulating tumor DNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma","volume":"85","author":"Huelster","year":"2024","journal-title":"Eur Urol"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"113368","DOI":"10.1016\/j.ejca.2023.113368","article-title":"Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer","volume":"195","author":"Helal","year":"2023","journal-title":"Eur J Cancer"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","article-title":"Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer","volume":"7","author":"Tolmeijer","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R41-20250824","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"R43-20250824","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/cas.15334","article-title":"Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma","volume":"113","author":"Nakano","year":"2022","journal-title":"Cancer Sci"},{"key":"R44-20250824","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","article-title":"Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"R45-20250824","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"R46-20250824","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.euf.2022.04.017","article-title":"Circulating tumour DNA is a strong predictor of outcomes in patients treated with systemic therapy for urothelial carcinoma","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"R47-20250824","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"R48-20250824","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.euo.2020.06.009","article-title":"Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder","volume":"3","author":"Rouanne","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"R49-20250824","doi-asserted-by":"crossref","first-page":"1887551","DOI":"10.1080\/2162402X.2021.1887551","article-title":"Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma","volume":"10","author":"Guo","year":"2021","journal-title":"Oncoimmunology"},{"key":"R50-20250824","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.6004\/jnccn.2017.7036","article-title":"Urothelial carcinoma of the bladder and the rise of immunotherapy","volume":"15","author":"Chism","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R51-20250824","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2019.05.002","article-title":"PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: a meta-analysis","volume":"76","author":"Ghate","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R52-20250824","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"R53-20250824","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R54-20250824","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"R55-20250824","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"key":"R56-20250824","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"key":"R57-20250824","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma","volume":"5","author":"Isharwal","year":"2019","journal-title":"Eur Urol Focus"},{"key":"R58-20250824","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"key":"R59-20250824","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2022.11.007","article-title":"Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors","volume":"21","author":"Chawla","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"R60-20250824","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J Urol"},{"key":"R61-20250824","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"R62-20250824","doi-asserted-by":"crossref","first-page":"e1003732","DOI":"10.1371\/journal.pmed.1003732","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:25:08Z","timestamp":1756063508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001372","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"2023-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}